Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

Simple item page
dc.contributor.authorGaultney, Jennifer G.
dc.contributor.authorSanhueza, Enrique
dc.contributor.authorJanssen, Jeroen J.
dc.contributor.authorRedekop, William K.
dc.contributor.authorUyl de Groot, Carin A.
dc.date.accessioned2024-01-10T13:11:11Z
dc.date.available2024-01-10T13:11:11Z
dc.date.issued2011
dc.description.abstractAim: A cost effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia. Materials & methods: A decision model was developed, and model inputs were taken from the literature and publicly available sources. The perspective of the healthcare sector in the Netherlands was used. Sensitivity and scenario analyses were performed to assess uncertainty in the results. Results: Companion diagnostics could improve health and reduce costs, despite the estimates being uncertain owing to limited evidence for comparative effectiveness between dasatinib and nilotinib. The results were sensitive to the cost of treatment, utility of progression and progression-free survival. Conclusion: This case demonstrates the use of cost effectiveness analysis at an early stage of health technology assessment to generate economic evidence for the use of companion diagnostics in treatment decisions and to support decision-making for their development.
dc.description.funderPamGene
dc.fechaingreso.objetodigital2024-05-17
dc.format.extent11 páginas
dc.fuente.origenWOS
dc.identifier.doi10.2217/PGS.10.187
dc.identifier.eissn1744-8042
dc.identifier.issn1462-2416
dc.identifier.pubmedidMEDLINE:21449679
dc.identifier.urihttps://doi.org/10.2217/PGS.10.187
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78011
dc.identifier.wosidWOS:000289707400019
dc.information.autorucMedicina;Sanhueza E ;S/I;12248
dc.issue.numero3
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final421
dc.pagina.inicio411
dc.publisherFUTURE MEDICINE LTD
dc.revistaPHARMACOGENOMICS
dc.rightsacceso restringido
dc.subjectchronic myeloid leukemia
dc.subjectcompanion diagnostics
dc.subjectcost-effectiveness analysis
dc.subjectdasatinib
dc.subjectnilotinib
dc.subjecttyrosine kinase inhibitors
dc.subjectCHRONIC MYELOGENOUS LEUKEMIA
dc.subjectLOW-DOSE CYTARABINE
dc.subjectCHRONIC-PHASE
dc.subjectCYTOGENETIC RESPONSE
dc.subjectUTILITY ANALYSIS
dc.subjectIMATINIB
dc.subjectNILOTINIB
dc.subjectDASATINIB
dc.subjectKINASE
dc.subjectINTERFERON
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleApplication of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
dc.typeartículo
dc.volumen12
sipa.codpersvinculados12248
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-17. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia.pdf
Size:
2.73 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas